- Home
- RMM vs CCCC Comparison
RMM vs CCCC Comparison
Compare RMM & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- CCCC
- Stock Information
- Founded
- RMM 2019
- CCCC 2015
- Country
- RMM United States
- CCCC United States
- Employees
- RMM N/A
- CCCC N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- RMM Finance
- CCCC Health Care
- Exchange
- RMM Nasdaq
- CCCC Nasdaq
- Market Cap
- RMM 271.2M
- CCCC 104.4M
- IPO Year
- RMM N/A
- CCCC 2020
- Fundamental
- Price
- RMM $13.77
- CCCC $2.26
- Analyst Decision
- RMM
- CCCC Buy
- Analyst Count
- RMM 0
- CCCC 3
- Target Price
- RMM N/A
- CCCC $12.00
- AVG Volume (30 Days)
- RMM 66.5K
- CCCC 1.6M
- Earning Date
- RMM 01-01-0001
- CCCC 07-31-2025
- Dividend Yield
- RMM 7.33%
- CCCC N/A
- EPS Growth
- RMM N/A
- CCCC N/A
- EPS
- RMM 0.96
- CCCC N/A
- Revenue
- RMM N/A
- CCCC $39,783,000.00
- Revenue This Year
- RMM N/A
- CCCC N/A
- Revenue Next Year
- RMM N/A
- CCCC N/A
- P/E Ratio
- RMM $15.55
- CCCC N/A
- Revenue Growth
- RMM N/A
- CCCC 98.56
- 52 Week Low
- RMM $12.32
- CCCC $1.09
- 52 Week High
- RMM $16.10
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- RMM 64.12
- CCCC 63.62
- Support Level
- RMM $13.51
- CCCC $1.36
- Resistance Level
- RMM $13.63
- CCCC $2.17
- Average True Range (ATR)
- RMM 0.09
- CCCC 0.15
- MACD
- RMM 0.04
- CCCC 0.05
- Stochastic Oscillator
- RMM 96.06
- CCCC 67.11
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.